Market Research Logo

Preimplantation Genetic Testing (PGT) Market Size & Forecast By Type (Chromosomal Abnormalities, X-Linked Diseases, Freeze Embryo Testing, Aneuploidy Screening, Human Leukocyte Antigen [HLA] Typing, Gender Selection), By Application (Embryo HLA Typing For

Preimplantation Genetic Testing (PGT) Market Size & Forecast By Type (Chromosomal Abnormalities, X-Linked Diseases, Freeze Embryo Testing, Aneuploidy Screening, Human Leukocyte Antigen [HLA] Typing, Gender Selection), By Application (Embryo HLA Typing For Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease, Screen Probands, Freeze Embryos), And Segment Forecasts To 2024

The global preimplantation genetic testing market was valued at USD 129.3 million in 2015 and is expected to reach a value of USD 221.1 million by 2024, according to a new report by Grand View Research, Inc. Growth in number of offspring born with inherited conditions is a high impact rendering factor for growth of this market. Emergence of preimplantation genetic diagnosis for detection of nearly all genetically inherited conditions enable couples, who are carriers of such conditions, screen their embryos before transferring to uterus and this is the primary driver of this industry.

Increase in adoption of IVF as a result of pregnancy-related complications is anticipated to drive demand for preimplantation genetic testing services. Women who are undergoing IVF are expected to undergo PGT cycles for prevention of inheritance of chromosomal abnormalities by offspring, which as a consequence is augmenting growth.

Growth in demand for these tests can be ascribed to the increase in rate of infertility due to environmental and lifestyle factors, which in turn, emphasizes the need for development in this vertical.

Further Key Findings From the Study Suggest:

Preimplantation genetic testing is available for different types of services, which include X-linked diseases, Human Leukocyte Antigen (HLA) typing, chromosomal abnormalities, freeze embryo testing, aneuploidy screening, detection of serious late-onset diseases, and gender selection. Preimplantation genetic testing for chromosomal abnormalities accounted for approximately 29% of the market share due to advancements in its screening by the use of noninvasive prenatal testing, which employs cell-free DNA for early detection of chromosomal abnormalities, such as Patau syndrome, Edwards syndrome, and Down syndrome.

This technology has various applications. Amongst all the applications, embryo HLA typing for stem cell therapy dominated with a share of over 30%. This largest share can be attributed to the benefits associated with the use of PGD for identification of HLA compatible embryos for stem cell therapy.

Although usage of these tests for inherited chromosomal disease is observed to have less penetration in the current scenario, it is expected to witness tremendous growth in the coming years due to increasing adoption rate of this service for detection of inherited genomic anomalies, such as sickle cell anemia and Huntington’s disease.

Europe accounted for the largest share with respect to revenue as a result of growing awareness about the scope of these diagnostic services for delivering genetically fit offspring. Also, developed infrastructure, rising investments by governmental bodies, and presence of key players in this region, collectively encourages growth of this industry in this region.

Some of the key players that have commercialized PGT services include F. Hoffmann-La Roche AG; Genea Limited; Quest Diagnostics, Illumina, Inc.; Natera, Inc; CooperSurgical, Inc; LabCorp; California Pacific Medical Center; Thermo Fisher Scientific, Inc; Igenomix; Reproductive Genetic Innovations, LLC; CombiMatrix; Good Start Genetics, Inc; Bioarray S.L; and Reproductive Health Science Ltd.

These key participants are actively involved in the R&D initiatives for development of novel PGT services. Partnership between entities and acquisition of small companies by major companies in order to reinforce its status in the market as well as to expand its product catalog for this vertical is expected boost revenue generation in preimplantation genetic diagnostics.

For instance, In December 2015, Natera, entered into a partnership with MedGenome, provider of genomic solutions for personalized healthcare in India. As per this partnership, MedGenome will be allowed to use the Panorama noninvasive prenatal test in its research laboratory. As a result, MedGenome becomes the first provider of this service in India.


Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
1.3 Base Market Build Up
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends& Scope
4.1 Market Segmentation & Scope
4.1.1 Market driver analysis
4.1.1.1 Rising incidence of genetic diseases
4.1.1.2 Demand for healthy and successful embryo implantation
4.1.1.3 Increase in rate of infertility
4.1.2 Market restraint analysis
4.1.2.1 Ethical and legal constraints
4.2 Penetration & Growth Prospect Mapping For Product Types, 2015
4.3 Global Preimplantation Genetic Testing Company Market Share, 2015
4.4 U.S. Preimplantation Genetic Testing Company Market Share, 2015
4.5 Platform Comparison
4.6 Preimplantation Genetic Testing (Screening/Diagnosis) PESTEL Analysis
4.7 Industry Analysis - Porter’s
Chapter 5 Market Categorization 1: Types Estimates & Trend Analysis
5.1 Global PGT Market: Types Movement Analysis
5.2 Chromosomal Abnormalities
5.2.1 Global chromosomal abnormalities market, 2013 - 2024 (USD million)
5.3 X-linked Diseases
5.3.1 Global X-linked diseases market, 2013 - 2024 (USD million)
5.4 Freeze Embryo Testing
5.4.1 Global freeze embryo testing market, 2013 - 2024 (USD million)
5.5 Aneuploidy Screening
5.5.1 Global aneuploidy screening market, 2013 - 2024 (USD million)
5.6 HLA Typing
5.6.1 Global HLA typing market, 2013 - 2024 (USD million)
5.7 Other PGT Types
5.7.1 Global other PGT types market, 2013 - 2024 (USD million)
Chapter 6 Market Categorization 2: Application Estimates & Trend Analysis
6.1 Global PGT Market: Application Movement Analysis
6.2 Identifying Embryo For Stem Cell Therapy
6.2.1 Global identifying embryo for stem cell therapy market, 2013 - 2024 (USD million)
6.3 IVF Prognosis
6.3.1 Global IVF prognosis for stem cell therapy market, 2013 - 2024 (USD million)
6.4 Late Onset Genetic Disorders
6.4.1 Global late onset genetic disorders market, 2013 - 2024 (USD million)
6.5 Inherited Genetic Disease
6.5.1 Global inherited genetic disease market, 2013 - 2024 (USD million)
6.6 Others
6.6.1 Global other PGT application market, 2013 - 2024 (USD million)
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Product& Application
7.1 Regional Movement Analysis & Market Share, 2015 & 2024
7.2 North America
7.2.1 North America PGT market, 2013 - 2024 (USD million)
7.2.2 U.S.
7.2.2.1 U.S PGT market, 2013 - 2024 (USD million)
7.2.3 Canada
7.2.3.1 Canada PGT market, 2013 - 2024 (USD million)
7.3 Europe
7.3.1 Europe PGT market, 2013 - 2024 (USD million)
7.3.2 Germany
7.3.2.1 Germany PGT market, 2013 - 2024 (USD million)
7.3.3 UK
7.3.3.1 UK PGT market, 2013 - 2024 (USD million)
7.4 Asia Pacific
7.4.1 Asia Pacific PGT market, 2013 - 2024 (USD million)
7.4.2 Japan
7.4.2.1 Japan PGT market, 2013 - 2024 (USD million)
7.4.3 China
7.4.3.1 China PGT market, 2013 - 2024 (USD million)
7.5 Latin America
7.5.1 Latin America PGT market, 2013 - 2024 (USD million)
7.5.2 Brazil
7.5.2.1 Brazil PGT market, 2013 - 2024 (USD million)
7.5.3 Mexico
7.5.3.1 Mexico PGT market, 2013 - 2024 (USD million)
7.6 Middle East & Africa
7.6.1 Middle East & Africa PGT market, 2013 - 2024 (USD million)
7.6.2 South Africa
7.6.2.1 South Africa PGT market, 2013 - 2024 (USD million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 F. Hoffmann-La Roche AG
8.3.1.1 Company overview
8.3.1.1.1 Ariosa Diagnostics
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 Genea Limited
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 Quest Diagnostics
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 Illumina, Inc.
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 Natera, Inc.
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 CooperSurgical, Inc.
8.3.6.1 Company overview
8.3.6.1.1 Genesis Genetics
8.3.6.1.2 Reprogenetics
8.3.6.2 Financial performance (Genesis Genetics)
8.3.6.3 Financial performance (Reprogenetics)
8.3.6.4 Product benchmarking
8.3.6.5 Strategic initiatives
8.3.7 Laboratory Corporation of America Holdings (LabCorp)
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 California Pacific Medical Center (CPMC)
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 Thermo Fisher Scientific Inc.
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.10 Igenomix
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 Reproductive Genetic Innovations, LLC. (RGI)
8.3.11.1 Company overview
8.3.11.2 Financial performance
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives
8.3.12 CombiMatrix
8.3.12.1 Company overview
8.3.12.2 Financial performance
8.3.12.3 Product benchmarking
8.3.12.4 Strategic initiatives
8.3.13 Good Start Genetics, Inc.
8.3.13.1 Company overview
8.3.13.2 Financial performance
8.3.13.3 Product benchmarking
8.3.13.4 Strategic initiatives
8.3.14 Bioarray S.L
8.3.14.1 Company overview
8.3.14.2 Financial performance
8.3.14.3 Product benchmarking
8.3.14.4 Strategic initiatives
8.3.15 Reproductive Health Science Ltd(RHS)
8.3.15.1 Company overview
8.3.15.2 Financial performance
8.3.15.3 Product benchmarking
8.3.15.4 Strategic initiatives
List of Tables
TABLE 1 Global incidence rate of genetic disorders
TABLE 2 Risk of aneuploidy with rising maternal age
TABLE 3 North America PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 4 North America PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 5 North America PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 6 North America PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 7 U.S.PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 8 U.S.PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 9 U.S.PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 10 U.S.PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 11 Canada PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 12 Canada PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 13 Canada PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 14 Canada PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 15 Europe PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 16 Europe PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 17 Europe PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 18 Europe PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 19 Germany PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 20 Germany PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 21 Germany PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 22 Germany PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 23 UK PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 24 UK PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 25 UK PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 26 UK PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 27 Asia Pacific PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 28 Asia Pacific PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 29 Asia Pacific PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 30 Asia Pacific PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 31 Japan PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 32 Japan PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 33 Japan PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 34 Japan PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 35 China PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 36 China PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 37 China PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 38 China PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 39 Latin America PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 40 Latin America PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 41 Latin America PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 42 Latin America PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 43 Brazil PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 44 Brazil PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 45 Brazil PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 46 Brazil PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 47 Mexico PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 48 Mexico PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 49 Mexico PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 50 Mexico PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 51 Middle East & Africa PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 52 Middle East & Africa PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 53 Middle East & Africa PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 54 Middle East & Africa PGT market forecasts, by application, 2016 - 2024 (USD million)
TABLE 55 South Africa PGT market estimates, by types, 2013 - 2015 (USD million)
TABLE 56 South Africa PGT market forecasts, by types, 2016 - 2024 (USD million)
TABLE 57 South Africa PGT market estimates, by application, 2013 - 2015 (USD million)
TABLE 58 South Africa PGT market forecasts, by application, 2016 - 2024 (USD million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Services available in different PGT centers
FIG. 8 Distribution of provided services
FIG. 9 Percentage of IVF-PGT clinics that perform in-house testing
FIG. 10 IVF treatment cycles started by type of eggs
FIG. 11 Market summary
FIG. 12 Market trends & outlook
FIG. 13 Market segmentation & scope
FIG. 14 Market driver relevance analysis (Current & future impact)
FIG. 15 Abnormality in oocytes with increasing maternal age
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 Penetration & growth prospect mapping for product types, 2015
FIG. 18 Global preimplantation genetic testing company market share, 2015
FIG. 19 U.S. preimplantation genetic testing company market share, 2015
FIG. 20 Illumina Veriseq PGS platform vs. Thermo Fisher Ion Torrent Reproseq PGS platform
FIG. 21 Preimplantation Genetic Testing (Screening/Diagnosis) PESTEL Analysis
FIG. 22 Porter’s Five Forces Analysis
FIG. 23 PGT market Types outlook key takeaways
FIG. 24 PGT market: Types movement analysis
FIG. 25 Global chromosomal abnormalities market, 2013 - 2024 (USD million)
FIG. 26 Global X-linked diseases market, 2013 - 2024 (USD million)
FIG. 27 Global freeze embryo testing market, 2013 - 2024 (USD million)
FIG. 28 Global aneuploidy screening market, 2013 - 2024 (USD million)
FIG. 29 Global HLA typing market, 2013 - 2024 (USD million)
FIG. 30 Global other PGT types market, 2013 - 2024 (USD million)
FIG. 31 PGT market: Application outlook key takeaways
FIG. 32 Global PGT market: Application movement analysis
FIG. 33 Global Identifying embryo for stem cell therapy market, 2013 - 2024 (USD million)
FIG. 34 Global IVF prognosis market, 2013 - 2024 (USD million)
FIG. 35 Global late onset genetic disorders market, 2013 - 2024 (USD million)
FIG. 36 Global inherited genetic disease market, 2013 - 2024 (USD million)
FIG. 37 Global other application market, 2013 - 2024 (USD million)
FIG. 38 Regional market place: Key takeaway
FIG. 39 PGT regional outlook , 2015 & 2024
FIG. 40 North America PGT market, 2013 - 2024 (USD million)
FIG. 41 U.S. PGT market, 2013 - 2024 (USD million)
FIG. 42 Canada PGT market, 2013 - 2024 (USD million)
FIG. 43 Europe PGT market, 2013 - 2024 (USD million)
FIG. 44 Germany PGT market, 2013 - 2024 (USD million)
FIG. 45 UK PGT market, 2013 - 2024 (USD million)
FIG. 46 Asia Pacific PGT market, 2013 - 2024 (USD million)
FIG. 47 Japan PGT market, 2013 - 2024 (USD million)
FIG. 48 China PGT market, 2013 - 2024 (USD million)
FIG. 49 Latin America PGT market, 2013 - 2024 (USD million)
FIG. 50 Brazil PGT market, 2013 - 2024 (USD million)
FIG. 51 Mexico PGT market, 2013 - 2024 (USD million)
FIG. 52 Middle East & Africa PGT market, 2013 - 2024 (USD million)
FIG. 53 South Africa PGT market, 2013 - 2024 (USD million)
FIG. 54 Strategy framework
FIG. 55 Participant categorization

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report